Assessment of the Impact of an Endpoint Committee in the Ocular Hypertension Treatment Study.
暂无分享,去创建一个
Alan L Robin | Richard K Parrish | Mae O Gordon | Michael A Kass | Eve J Higginbotham | Dale K Heuer | Patricia A Morris | Deborah A Dunn | Bradley S Wilson
[1] P. Lichter,et al. The Collaborative Initial Glaucoma Treatment Study: study design, methods, and baseline characteristics of enrolled patients. , 1999, Ophthalmology.
[2] B. Kahan,et al. A comparison of approaches for adjudicating outcomes in clinical trials , 2017, Trials.
[3] T. Dawber,et al. The Framingham Eye Study monograph: An ophthalmological and epidemiological study of cataract, glaucoma, diabetic retinopathy, macular degeneration, and visual acuity in a general population of 2631 adults, 1973-1975. , 1980, Survey of ophthalmology.
[4] M. Bhandari,et al. Adjudicating outcomes: fundamentals. , 2012, The Journal of bone and joint surgery. American volume.
[5] E. E. Hartmann,et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. , 2002, Archives of ophthalmology.
[6] D. Hood,et al. Challenges to the Common Clinical Paradigm for Diagnosis of Glaucomatous Damage With OCT and Visual Fields , 2018, Investigative ophthalmology & visual science.
[7] Nicholas G Strouthidis,et al. Optic disc and visual field progression in ocular hypertensive subjects: detection rates, specificity, and agreement. , 2006, Investigative ophthalmology & visual science.
[8] Chris A Johnson,et al. Baseline visual field characteristics in the ocular hypertension treatment study. , 2002, Ophthalmology.
[9] M. C. Leske,et al. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. , 2002, Archives of ophthalmology.
[10] D E Gaasterland,et al. The Advanced Glaucoma Intervention Study (AGIS): 1. Study design and methods and baseline characteristics of study patients. , 1994, Controlled clinical trials.
[11] M. Kass,et al. The Ocular Hypertension Treatment Study: design and baseline description of the participants. , 1999, Archives of ophthalmology.
[12] C. Ramsay,et al. Outcome Measures in Glaucoma: A Systematic Review of Cochrane Reviews and Protocols , 2015, Journal of glaucoma.
[13] D P Crabb,et al. Interobserver agreement on visual field progression in glaucoma: a comparison of methods , 2003, The British journal of ophthalmology.
[14] Wenle Zhao,et al. Architecture design of a generic centralized adjudication module integrated in a web-based clinical trial management system , 2016, Clinical trials.
[15] W. Feuer,et al. Five-year follow-up optic disc findings of the Collaborative Initial Glaucoma Treatment Study. , 2009, American journal of ophthalmology.
[16] Jonathan H Seltzer,et al. Use of endpoint adjudication to improve the quality and validity of endpoint assessment for medical device development and post marketing evaluation: Rationale and best practices. A report from the cardiac safety research consortium , 2017, American heart journal.
[17] S. Yusuf,et al. Evaluating the benefit of event adjudication of cardiovascular outcomes in large simple RCTs , 2009, Clinical trials.
[18] Douglas R. Anderson,et al. The Ocular Hypertension Treatment Study: reproducibility of cup/disk ratio measurements over time at an optic disc reading center. , 2002, American journal of ophthalmology.
[19] Richard A. Russell,et al. Latanoprost for open-angle glaucoma (UKGTS): a randomised, multicentre, placebo-controlled trial , 2015, The Lancet.
[20] J L Keltner,et al. Confirmation of visual field abnormalities in the Ocular Hypertension Treatment Study. Ocular Hypertension Treatment Study Group. , 2000, Archives of ophthalmology.
[21] S. Mansberger,et al. Primary Open-Angle Glaucoma Suspect Preferred Practice Pattern(®) Guidelines. , 2016, Ophthalmology.